Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared a post on X:
“Survey re: RT use in pancreas cancer in Europe.
Like US, practice patterns vary widely- LAPC s/p chemo: 42% chemoRT, 23% SBRT, 35% chemo alone.
If at NRG credentialed site in Europe & interested in enrolling in LAP100 (Ph III RCT of dose-escalated RT in LAPC), let me know!”
More posts featuring Pancreatic Cancer on OncoDaily.